Orvirem syrup 2mg / ml 100ml

Description

Composition
Active substance:
5 ml of syrup contains 10 mg of rimantadine hydrochloride.
Excipients:
Sugar, sodium alginate, E122, purified water.
Description:
Thick liquid pink or light red in color.
Product form:
Syrup for oral administration of 2 mg / ml. Dark glass vials / bottles of liquid dosage forms of polyethylene terephthalate of 100 ml. The vial together with instructions for use placed in a pile of cardboard.
Contraindications
Acute liver disease; acute and chronic renal disease; hyperthyroidism; Pregnancy and lactation; Children up to 1 year; hypersensitivity to the drug component and rimantadine; deficit sucrase / isomaltase; fructose intolerance; glucose-galactose malabsorption.
Carefully
Epilepsy (including history), severe chronic renal failure, liver failure, diabetes.
Dosage
2 mg / ml
Indications
Prevention and treatment of influenza and acute respiratory viral infections in children from 1 year to 7 years.
Interaction with other drugs
Pharmacodynamic: Rimantadine reduces the effectiveness of anti-epileptic drugs.
Pharmacokinetic: adsorbents, binders and cathartic agents reduce the absorption of rimantadine.
Atsidifiruyuschie urine agents (acetazolamide, sodium hydrogencarbonate, etc.) Increase the concentration of rimantadine.
Paracetamol and ascorbic acid reduce the maximum concentration in the blood plasma of rimantadine by 11%.
Cimetidine rimantadine clearance decreases by 18%.
Overdose
Cases of overdose have been observed.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacological properties:
Orvirem – a durable polymeric salt complex drug rimantadine natural polymer compound – sodium alginate. Due to its pharmacological properties that are substantially modified compared to conventional rimantadine. Part of the drug-modified low molecular weight sodium alginate besides performing the function of the polymer matrix and detoxication has absorbent properties, which contributes to its anti-toxic activity. Orvirema circulation time in plasma higher than that of rimantadine, and diffusion rate in the tissue is substantially reduced, thus reducing the dosage of the drug, and, therefore, significantly reduce the risk of adverse effects and provide a good portability when used.
Mechanism of action
The peculiarity of the drug is that it rimantadine is fixed on a matrix of sodium alginate. This allows Orviremu provide prolonged circulation of the drug, while reducing its toxicity, because in the dosage form rimantadine released immediately, which makes it a long and gradual delivery to the blood. This reduces the degree of rimantadine toxicity, improved pharmacokinetics and drug action mechanism, which is now well understood. Antiviral effect Orvirema implemented by special blocking virus M2 ion channel, which is accompanied by breach of its ability to penetrate into cells. As a lipotropic, rimantadine has an inhibitory effect on the synthesis of M-protein of influenza virus, thereby breaking the reproduction process and assembly of full virions.
This explains the high specificity of rimantadine against influenza A viruses and the highest efficiency in the treatment of influenza infection. Rimantadine no effect on influenza B and other respiratory viruses, although, because of the properties of the electron shell of the drug and its attractiveness membrannotropnoy, rimantadine has antitoxic effect and the ability to inhibit the reproduction of these viruses at 30-65%.
Pharmacodynamics:
From Orvirema being rimantadine polymeric compound with sodium alginate, the active ingredient is released at once, which causes a gradual rimantadine delivery into the blood, it prolonged circulation in the body, a constant concentration of drug in the blood, reducing the toxic effect of rimantadine.
It is active against strains of influenza virus A (especially type A2).
It has a toxic effect at SARS and the flu caused by virus type B.
Pharmacokinetics:
After oral administration almost completely absorbed from the gastrointestinal tract, the Cmax is reached after 5.5 hours in plasma. It is metabolized to form hydroxylated compounds half-life of – 25-30 hrs. Excreted mainly by the kidneys in unchanged form (25%) and in the form of metabolites.
Conditions of supply of pharmacies
On prescription.
side effects
On the part of the gastrointestinal tract: nausea, vomiting, epigastric pain, flatulence, anorexia;
Central nervous system: headache, dizziness, insomnia, neurological reactions, impaired concentration;
Other: hyperbilirubinemia, allergic reactions (skin rash, pruritus, urticaria), asthenia.
special instructions
Application rimantadine for 2-3 days before and 6-7 hours after the onset of clinical manifestations of influenza type A reduces the severity of symptoms and the degree of serological reactions. Some therapeutic effect may also occur if rimantadine assigned within 18 hours after appearance of the first symptoms of influenza.
In use, may exacerbation of chronic comorbidities. For epilepsy patients during treatment with rimantadine increased risk of seizures.
15 corresponds to 1 ml of syrup bread units (BU) that should be considered when administering the drug to patients with diabetes. Perhaps the emergence of drug-resistant viruses.
Given the likelihood of adverse effects on the central nervous system, caution should be exercised when driving and mechanisms.
Storage conditions
Store in a dark place at a temperature not higher than 25 ° C. Keep out of the reach of children.
Dosing and Administration
Orvirem taken orally after meal with water, the following schemes (1 teaspoon = 5 ml):
Prevention.
Age-1-3 years 10 mL (2 tsp.). 1 times a day for 10-15 days;
Age 3-7 years and 15 ml (3 tsp.). 1 times a day for 10-15 days;
Over 7 to 25 ml (5 hours. L.), 1 times a day for 10-15 days.
Treatment.
Age, 1-3 years:
1 den 10 mL (2 tsp..) – 3 times a day; 2-3 day- 10 mL (2 tsp..) – 2 times a day for 4-5 day- 10 mL (2 tsp.). – 1 time per day.
Age, 3-7 years:
1 den 15 ml (3 tsp..) – 3 times a day; 2-3 day- 15 ml (3 tsp..) – 2 times a day; 4-5 times a day or 15 ml (3 tsp..) – 1 times per day.
Age older than 7 years old:
1 den 25 ml (5 tsp..) – 2 times a day; 2-3 day or 25 ml (5 tsp..) – 2 times a day; 4-5 day- 25 ml (5 tsp.). – 1 time per day.
Attention! Rimantadine daily dose should not exceed 5 mg per kg body weight.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist